TPST ▲ +27.3% - Tempest Therapeutics, Inc. $TPST - Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform Tempest Therapeutics surged 27.3% after securing an exclusive option to license a clinical-stage CD7-targeted lentiviral in vivo CAR-T platform, potentially expanding its pipeline with an advanced cell therapy approach. The deal gives the company rights to a promising immunotherapy technology, which investors viewed as a significant strategic addition to its oncology portfolio. 15-SEP-2026 04:05 PM ET